Journal Mobile Options
Table of Contents
Vol. 23, No. 5, 2007
Issue release date: April 2007
Dement Geriatr Cogn Disord 2007;23:281–288

Cognitive Changes in Parkinson’s Disease Patients with Visual Hallucinations

Ramirez-Ruiz B. · Junque C. · Marti M.-J. · Valldeoriola F. · Tolosa E.
aInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), bDepartment of Psychiatry and Clinical Psychobiology, University of Barcelona, cParkinson’s Disease and Movement Disorders Unit, Neurology Service, Institut Clínic de Neurociències, Hospital Clínic Universitari, University of Barcelona, Barcelona, Spain

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Objective: To evaluate the decline in specific neuropsychological functions in nondemented Parkinson’s disease (PD) patients with a history of visual hallucinations (VH). Methods: Twenty PD patients with VH, 20 PD patients without VH and 18 normal controls were followed up over a 1-year period and assessed for cognitive decline. Results: Forty-five percent of nondemented hallucinating PD patients developed dementia during the 1-year period between baseline and follow-up evaluations. Of the nondemented hallucinating PD patients nearly 70% showed impairment in multiple cognitive domains. The progressive decline in hallucinating PD patients affected mainly visual memory for faces and visuoperceptive-visuospatial functions. Conclusion: Our results support a fast impairment of complex visual functions in hallucinating PD patients, but also a progressive decline in multiple cognitive domains, which have been identified as a risk of developing dementia in PD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Williams DR, Lees AJ: Visual hallucinations in the diagnosis of idiopathic Parkinson’s disease: a retrospective autopsy study. Lancet Neurol 2005;4:605–610.
  2. Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P: Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriatr Psychiatry 2005;20: 668–673.
  3. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E: Neuropsychological deficits in Parkinson’s disease patients with visual hallucinations. Mov Disord 2006 on-line. DOI:10.1002/mds.20965.
  4. Sinforiani E, Zangaglia R, Manni R, Cristina S, Marchioni E, Nappi G, Mancini F, Pacchetti C: REM sleep behavior disorder, hallucinations, and cognitive impairment in Parkinson’s disease. Mov Disord 2006;21:462–466.
  5. Barnes J, Boubert L, Harris J, Lee A, David AS: Reality monitoring and visual hallucinations in Parkinson’s disease. Neuropsychologia 2003;41:565–574.
  6. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P: Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387–392.
  7. Aarsland D, Andersen K, Larsen JP, Perry R, Wentzel-Larsen T, Lolk A, Kragh-Sorensen P: The rate of cognitive decline in Parkinson disease. Arch Neurol 2004;61:1906–1911.
  8. Daniel SE, Lees AJ: Parkinson’s Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993;39:165–172.
  9. Larsen JP, Dupont E, Tandberg E: Clinical diagnosis of Parkinson’s disease: proposal of diagnostic subgroups classified at different levels of confidence. Acta Neurol Scand 1994;89:242–251.
  10. Fahn S, Elton RL, and members of the UPDRS Development Committee Unified Parkinson’s Disease Rating Scale; in Fahn S, Marsden CD, Calne DB, Lieberman A (eds): Recent Developments in Parkinson’s Disease. Florham Park, McMillan Health Care Information, 1987, pp 153–163.
  11. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, Tanner C, Weiner W and the Parkinson Study Group: Variable expression of Parkinson’s disease: a base-line analysis of the DATATOP cohort. Neurology 1990;40:1529–1534.
  12. Goetz CG, Blasucci LR, Stebbins GT: Switching dopamine agonist in advanced Parkinson’s disease: is rapid titration preferable to slow? Neurology 1999;52:1227–1229.
  13. Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J: Subthalamic DBS replaces levodopa in Parkinson’s disease: two-year follow-up. Neurology 2002;58:396–401.
  14. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
  15. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–2314.
  16. Benton AL, Sivan AB, Hamsher K, Varney NR, Spreen O: Contributions to Neuropsychological Assessment. New York, Oxford University Press, 1994.
  17. Spreen O, Strauss E (eds) : A Compendium of Neuropsychological Tests: Administration, Norms and Commentary, ed 2. New York, Oxford University Press, 1998.
  18. Janvin CC, Larsen JP, Aarsland D, Hugdahl K: Subtypes of mild cognitive impairment in Parkinson’s disease: progression to dementia. Mov Disord 2006 on-line. DOI:10.1002/mds.20974.
  19. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308.
  20. American Psychiatric Association: Manual diagnóstico y estadístico de los trastornos mentales, cuarta edición revisada: DSM-IV-TR. Barcelona, Masson, 2003.
  21. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  22. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R and the Parkinson Study Group: Longitudinal outcome of Parkinson’s disease patients with psychosis. Neurology 2003;60:1756–1761.
  23. Rapcsak SZ: Face memory and its disorders. Curr Neurol Neurosci Rep 2003;3:494–501.
  24. Harding AJ, Broe GA, Halliday GM: Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391–403.
  25. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H: Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005;65:1708–1715.
  26. Rao H, Zhou T, Zhuo Y, Fan S, Chen L: Spatiotemporal activation of the two visual pathways in form discrimination and spatial location: a brain mapping study. Hum Brain Mapp 2003;18:79–89.
  27. Davidsdottir S, Cronin-Golomb A, Lee A: Visual and spatial symptoms in Parkinson’s disease. Vision Res 2005;45:1285–1296.
  28. Collerton D, Perry E, McKeith I: Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005;28:737–794.
  29. Diederich NJ, Goetz CG, Stebbins GT: Repeated visual hallucinations in Parkinson’s disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005;20:130–140.
  30. Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, Gabrieli JDE: Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004;63:1409–1416.
  31. Nagano-Saito A, Washimi Y, Arahata Y, Iwai K, Kawatsu S, Ito K, Nakamura A, Abe Y, Yamada T, Kato T, Kachi T: Visual hallucination in Parkinson’s disease with FDG PET. Mov Disord 2004;19:801–806.
  32. Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC: Cortical and amygdalar Lewy body burden in Parkinson’s disease patients with visual hallucinations. Parkinsonism Relat Disord 2006;12:253–256.
  33. Bosboom JLW, Stoffers D, Wolters ECh: Cognitive dysfunction and dementia in Parkinson’s disease. J Neural Transm 2004;111:1303–1315.
  34. Papapetropoulos S, Mash DC: Psychotic symptoms in Parkinson’s disease: from description to etiology. J Neurol 2005;252:753–764.
  35. Braak H, Rub U, Jansen Steur EN, Del Tredici K, de Vos RA: Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 2005;64:1404–1410.
  36. Hobson P, Meara J: Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom. Mov Disord 2004;19:1043–1049.
  37. Jacobs DM, Marder K, Cote LJ, Sano M, Stern Y, Mayeux R: Neuropsychological characteristics of preclinical dementia in Parkinson’s disease. Neurology 1995;45:1691–1696.
  38. Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B, Mejia H, Stern Y, Marder K: Memory and executive function impairment predict dementia in Parkinson’s disease. Mov Disord 2002;17:1221–1226.
  39. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sorensen P: Risk of dementia in Parkinson’s disease: a community-based, prospective study. Neurology 2001;56:730–736.
  40. Janvin CC, Aarsland D, Larsen JP: Cognitive predictors of dementia in Parkinson’s disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005;18:149–154.
  41. Burton EJ, McKeith IG, Burn DJ, O’Brien JT: Brain atrophy rates in Parkinson’s disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005;20:1571–1576.
  42. Firbank MJ, Molloy S, McKeith IG, Burn DJ, O’Brien JT: Longitudinal change in 99mTcHMPAO cerebral perfusion SPECT in Parkinson’s disease over one year. J Neurol Neurosurg Psychiatry 2005;76:1448–1451.
  43. Levin BE, Llabre MM, Reisman S, Weiner WJ, Sanchez-Ramos J, Singer C, Brown MC: Visuospatial impairment in Parkinson’s disease. Neurology 1991;41:365–369.
  44. Woods SP, Troster AI: Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson’s disease. J Int Neuropsychol Soc 2003;9:17–24.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50